NCT05159817 (SAFARI FU) is a clinical trial in Glaucoma, Open-Angle, sponsored by Ciliatech.

Who is sponsoring NCT05159817?

NCT05159817 is sponsored by Ciliatech.

What condition does NCT05159817 study?

NCT05159817 studies Glaucoma, Open-Angle.

Is NCT05159817 still recruiting?

NCT05159817 is currently status unknown. Last updated 13 February 2023.

Last reviewed 2023-02-13 · How we verify

NCT05159817: SAFARI FU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Status unknown Last updated 13 February 2023

What this trial tests

trial in Glaucoma, Open-Angle in 19 participants. Status unknown.

Timeline

15 December 2021

Primary endpoint
28 February 2024

31 December 2024

Quick facts

Lead sponsor	Ciliatech
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	19
Start date	15 December 2021
Primary completion	28 February 2024
Estimated completion	31 December 2024
Sites	1 location across Armenia

Conditions studied

Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →

Sponsor

Ciliatech

Who can join

50 and older, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma, Open-Angle

Currently open trials in the same condition.

NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting

Other Ciliatech trials

Trials by the same sponsor.

NCT05625958 — Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery · NA · recruiting
NCT05236439 — Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Gl · NA · active not recruiting
NCT04770324 — Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2) · NA · terminated
NCT03736655 — Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05159817 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ciliatech
Last refreshed: 13 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05159817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing